Zika Virus Disease Enhanced Surveillance – Postnatally a

Zika Virus Enhanced Surveillance of Selected Populations

Att. 4 - Enhanced surveillance - children

Zika Virus Disease Enhanced Surveillance – Postnatally acquired Zika virus disease among children aged

OMB: 0920-1192

Document [docx]
Download: docx | pdf

Form Approved

OMB Control No. 0920-XXXX

Exp. date: XX/XX/XXXX

Attachment 4: Zika Virus Disease Enhanced Surveillance – Postnatally acquired Zika virus disease among children aged <18 years

Demographic Information

Case ID (ArboNET):_____________________ Control for Case ID:____________________

State of residence:_____________________ County of residence:___________________

Age: ______ Years Months Days Sex: Male Female

Pregnant: Yes No Unknown Est Date Delivery: ____/____/____ OR Last Menstrual Period: ____/____/____

Race (Select all appropriate): American Indian or Alaska Native Asian Black or African American

Native Hawaiian or Other Pacific Islander White Other Unknown

Ethnicity: Hispanic or Latino Not Hispanic or Latino Unknown

Co-morbidities: Yes No Unknown Describe:_______________________________________________________

Imported From: Not Imported Acquired Out of State Acquired Out of Country Unknown

Country of Origin:________________________________ Travel dates:____________________________

State of Origin:__________________________________ Travel dates: ____________________________

Other possible exposures: Sexual Breastfeeding Blood products Organs

Clinical Information

Illness onset date: _____/_____/_____

Clinical syndrome: Febrile illness Encephalitis/meningoencephalitis Meningitis Acute flaccid paralysis

Guillain-Barré syndrome Other neuroinvasive presentation Other clinical______________________

Case Status (ArboNET): Confirmed Probable

Fever

Yes No Unk Subjective Measured (Max temperature: __________)

Chills/Rigors

Yes No Unk

Rash

Yes No Unk Type: Maculopapular Petechial Purpuric

Other:____________________________________________

Pruritic: Yes No Unk

Distribution:­­­­­­­_______________________________________________

Headache

Yes No Unk

Retro-orbital pain

Yes No Unk

Conjunctivitis

Yes No Unk

Oral ulcers

Yes No Unk

Nausea/Vomiting

Yes No Unk

Diarrhea

Yes No Unk

Arthralgia

Yes No Unk

Arthritis

Yes No Unk

Myalgia

Yes No Unk

Paresis/Paralysis

Yes No Unk

Stiff Neck

Yes No Unk

Ataxia

Yes No Unk

Altered mental status

Yes No Unk

Seizures

Yes No Unk

Clinical Information (continued)

Sore throat

Yes No Unk

Cough

Yes No Unk

Lymphadenopathy

Yes No Unk

Paresthesia

Yes No Unk

Abdominal pain

Yes No Unk

Edema

Yes No Unk Specify:__________________________________________________

CBC performed

Yes No Unk Leukopenia Yes (<4,500) Nadir:________ No Unk

Thrombocytopenia Yes (<150,000) Nadir:_______ No Unk

LP performed

Yes No Unk CSF Pleocytosis Yes No Unk (WBC count >=5)

Other

Yes No Unk Specify:__________________________________________________

Outcomes

Emergency department

Yes No Unk


Hospitalized

Yes No Unk

Admission Date: _____/_____/_____

Discharge Date:_____/_____/_____ OR

Days hospitalized:______________

Died

Yes No Unk

Date of Death:_____/_____/_____

Zika Virus Test Results

Dengue Virus Test Results

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial

Specimen collected: _____/_____/_____

Specimen Type: Serum CSF Urine

Test: IgM PRNT PCR/NAT IHC

Result: Positive Negative Equivocal

Performing Lab: CDC State PH Commercial





Public reporting burden of this collection of information is estimated to average XX minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information.  An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB Control Number.  Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer, 1600 Clifton Road NE, MS D-74, Atlanta, Georgia 30333; ATTN: PRA 0920-XXXX   

File Typeapplication/vnd.openxmlformats-officedocument.wordprocessingml.document
AuthorSamuel, Lee (CDC/OID/NCEZID)
File Modified0000-00-00
File Created2021-01-22

© 2024 OMB.report | Privacy Policy